| 0.85 -0.127 (-12.97%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.58 | 1-year : | 1.98 |
| Resists | First : | 1.35 | Second : | 1.7 |
| Pivot price | 1.19 |
|||
| Supports | First : | 0.8 | Second : | 0.66 |
| MAs | MA(5) : | 0.91 |
MA(20) : | 1.29 |
| MA(100) : | 1.52 |
MA(250) : | 3.02 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 15.8 |
D(3) : | 15.1  |
| RSI | RSI(14): 25 |
|||
| 52-week | High : | 8.36 | Low : | 0.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SCLX ] has closed above bottom band by 11.1%. Bollinger Bands are 23.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.93 - 0.94 | 0.94 - 0.94 |
| Low: | 0.82 - 0.82 | 0.82 - 0.83 |
| Close: | 0.84 - 0.85 | 0.85 - 0.86 |
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Wed, 24 Apr 2024
It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks - Simply Wall St
Wed, 24 Apr 2024
Scilex Holding Company Announces $15 Million Registered Direct Offering - Yahoo Finance
Wed, 27 Mar 2024
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of ... - Yahoo Finance
Mon, 25 Mar 2024
Scilex Holding Ends Equity Purchase Deal with Yorkville - TipRanks.com - TipRanks
Thu, 21 Mar 2024
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients - GlobeNewswire
Fri, 15 Mar 2024
Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 106 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 37.7 (%) |
| Held by Institutions | 16 (%) |
| Shares Short | 6,580 (K) |
| Shares Short P.Month | 7,240 (K) |
| EPS | -1.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.74 |
| Profit Margin | -244.7 % |
| Operating Margin | -136.3 % |
| Return on Assets (ttm) | -70.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 12.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.44 |
| EBITDA (p.s.) | -0.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | 34 (M) |
| PE Ratio | -0.67 |
| PEG Ratio | 0 |
| Price to Book value | -0.5 |
| Price to Sales | 1.92 |
| Price to Cash Flow | -4.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|